Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 20/20 | 0.72 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22771316 | 0.89 | TLR8 (0.76) | TLR8TLR7 | |
| SCHEMBL23204276 | 0.87 | TLR8 (0.70) | TLR8TLR7 | |
| SCHEMBL22771195 | 0.85 | TLR8 (0.49) | TLR8TLR7 | |
| SCHEMBL22796634 | 0.85 | TLR8 (0.67) | TLR8TLR7 | |
| SCHEMBL18041279 | 0.85 | TLR8 (1.00) | TLR8TLR7 | |
| SCHEMBL24698694 | 0.84 | TLR8 (0.65) | TLR8TLR7 | |
| SCHEMBL22783809 | 0.82 | TLR8 (0.81) | TLR8TLR7 | |
| SCHEMBL29778139 | 0.82 | TLR8 (0.81) | TLR8TLR7 | |
| SCHEMBL23204448 | 0.81 | TLR8 (0.64) | TLR8TLR7 | |
| SCHEMBL22783938 | 0.81 | TLR8 (0.86) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220347310-A1 | AMIDE-LINKED, AMINOBENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-11-03 | — | — | US | disclosed |
| EP-4038053-A1 | AMIDE-LINKED, AMINOBENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| WO-2021067242-A1 | AMIDE-LINKED, AMINOBENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021067242-A1 | AMIDE-LINKED, AMINOBENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347310-A1 | AMIDE-LINKED, AMINOBENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | AADAC, IGLV6-57, BCR | TLR8 535/4885TLR7 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.